0 CHECKOUT

Oral Mucositis - Pipeline Review, H2 2015

  • ID: 3429831
  • August 2015
  • 97 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Clevexel Pharma SAS
  • Intrexon Corporation
  • Onxeo SA
  • Otsuka Holdings Co., Ltd.
  • ProCertus BioPharm Inc.
  • MORE

Oral Mucositis - Pipeline Review, H2 2015

Summary

The report ‘Oral Mucositis - Pipeline Review, H2 2015’, provides an overview of the Oral Mucositis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corporation
  • Clevexel Pharma SAS
  • Intrexon Corporation
  • Onxeo SA
  • Otsuka Holdings Co., Ltd.
  • ProCertus BioPharm Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Oral Mucositis Overview

Therapeutics Development

Pipeline Products for Oral Mucositis - Overview

Pipeline Products for Oral Mucositis - Comparative Analysis

Oral Mucositis - Therapeutics under Development by Companies

Oral Mucositis - Therapeutics under Investigation by Universities/Institutes

Oral Mucositis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Oral Mucositis - Products under Development by Companies

Oral Mucositis - Products under Investigation by Universities/Institutes

Oral Mucositis - Companies Involved in Therapeutics Development

Aldeyra Therapeutics, Inc.

Cellceutix Corporation

Clevexel Pharma SAS

Colby Pharmaceutical Company

Daewoong Pharmaceutical Co., Ltd.

Intrexon Corporation

Laila Pharmaceuticals Pvt. Ltd.

Onxeo SA

Otsuka Holdings Co., Ltd.

ProCertus BioPharm Inc.

Soligenix, Inc.

Spectrum Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

Oral Mucositis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AG-013 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AP-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AP-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

clonidine hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cobiprostone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CVXL-0095 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GC-4403 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GC-4419 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for Oral Mucositis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JVRSOD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LP-00409 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nepidermin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NS-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OralX - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rebamipide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Regenasyn - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oral Mucositis - Recent Pipeline Updates

Oral Mucositis - Dormant Projects

Oral Mucositis - Discontinued Products

Oral Mucositis - Product Development Milestones

Featured News & Press Releases

Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis

Jun 18, 2015: Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive until 2029

Jun 01, 2015: Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers

May 26, 2015: Onxeo Announces Final Data from Completed Phase II Trial of Validive for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients

May 07, 2015: FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis

May 06, 2015: Oral Presentation of Phase II Trial Results of Validive at the MASCC/ISOO International Symposium

Apr 23, 2015: Aldeyra Therapeutics Abstract Accepted for Presentation at the 2015 Multinational Association of Supportive Care in Cancer - International Society of Oral Oncology Annual Meeting

Apr 02, 2015: Phase II trial results of Validive presented at the ASCO Conference

Mar 03, 2015: Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Jan 05, 2015: Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Oral Mucositis, H2 2015

Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015

Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2015

Oral Mucositis - Pipeline by Clevexel Pharma SAS, H2 2015

Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2015

Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015

Oral Mucositis - Pipeline by Intrexon Corporation, H2 2015

Oral Mucositis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2015

Oral Mucositis - Pipeline by Onxeo SA, H2 2015

Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015

Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H2 2015

Oral Mucositis - Pipeline by Soligenix, Inc., H2 2015

Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Oral Mucositis Therapeutics - Recent Pipeline Updates, H2 2015

Oral Mucositis - Dormant Projects, H2 2015

Oral Mucositis - Dormant Projects (Contd..1), H2 2015

Oral Mucositis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Oral Mucositis, H2 2015

Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Aldeyra Therapeutics, Inc.
Cellceutix Corporation
Clevexel Pharma SAS
Colby Pharmaceutical Company
Daewoong Pharmaceutical Co., Ltd.
Intrexon Corporation
Laila Pharmaceuticals Pvt. Ltd.
Onxeo SA
Otsuka Holdings Co., Ltd.
ProCertus BioPharm Inc.
Soligenix, Inc.
Spectrum Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Purdue Pharma L.P.
  • Almirall, S.A.